Last reviewed · How we verify

NCT03042130

Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency

Withdrawn Phase 4 Last updated 28 February 2018
What this trial tests

Phase 4 trial testing Standard of care in Heart Failure. Withdrawn.

Timeline
14 December 2016
Primary endpoint
6 February 2018
6 February 2018

Quick facts

Lead sponsorTel-Aviv Sourasky Medical Center
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Start date14 December 2016
Primary completion6 February 2018
Estimated completion6 February 2018
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Tel-Aviv Sourasky Medical Center

Who can join

Adults 18 to 120, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Standard of care

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Tel-Aviv Sourasky Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03042130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing